The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

May. 11, 2017
Applicants:

The University of Chicago, Chicago, IL (US);

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v., Munich, DE;

Inventors:

Ernst Lengyel, Chicago, IL (US);

Matthias Mann, Munich, DE;

Marion Curtis, Chicago, IL (US);

Fabian Coscia, Munich, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 45/06 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); A61K 31/337 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01); A61K 31/555 (2006.01); A61K 31/706 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4748 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 31/706 (2013.01); A61K 33/243 (2019.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 38/2013 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57449 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2501/02 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2301 (2013.01); C12N 2501/25 (2013.01); G01N 2800/52 (2013.01);
Abstract

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.


Find Patent Forward Citations

Loading…